The EPO published patent application EP4017970A1 for a biotechnological manufacturing process of antigen-specific T lymphocytes, a type of immune cell therapy. The patent grants exclusive rights to the Medical University of Gdańsk (Gdanski Uniwersytet Medyczny) with designated states covering all EU member states, Switzerland, and other European countries.\n\nPharmaceutical companies and healthcare providers engaged in cell therapy development should review this patent to assess freedom-to-operate implications for any related research or commercial activities. No immediate compliance actions are required as patent grants do not impose regulatory obligations on third parties.